Bone-Targeted Therapy Guidelines

Introduction to Bone-Targeted Therapy

The European Society for Medical Oncology (ESMO) guidelines recommend using one bone-targeted agent at a time, with denosumab as first-line treatment followed by bisphosphonates for sequential use, not concurrent use 1, 2.
The American College of Clinical Oncology and other major guidelines agree that denosumab and bisphosphonates should never be used together in clinical practice, as it increases the risk of severe adverse events without additional clinical benefit 1, 2, 3.

The National Comprehensive Cancer Network (NCCN) recommends that patients on androgen deprivation therapy (ADT) for prostate cancer should receive denosumab 60 mg subcutaneously every 6 months as the preferred first-line treatment, as it has the strongest evidence for fracture prevention, reducing vertebral fractures by 62% in the HALT study 1, 2.
For patients not on ADT, treatment indication depends on T-score and fracture risk factors, with bone-targeted therapy indicated for T-score <-2.0 or T-score >-2.0 with ≥2 risk factors, including age >65, smoking history, low BMI, personal history of fragility fracture, family history of hip fracture, and glucocorticoid use 1, 2.
The ESMO guidelines specifically recommend denosumab as first-line for men on ADT, and alternative acceptable options include zoledronic acid, alendronate, risedronate, and ibandronate, with specific dosing and administration instructions 1, 2, 4, 6.

The use of denosumab and bisphosphonates requires careful consideration of safety risks, including severe hypocalcemia, osteonecrosis of the jaw (ONJ), atypical femoral fractures, and esophageal complications, with specific warnings and precautions for each agent 1, 4, 5, 6.
Patients receiving denosumab must have baseline serum calcium level, vitamin D level, and renal function assessed, and must receive calcium and vitamin D supplementation, with regular monitoring of these parameters 5, 6.
Patients receiving ibandronate must have adequate renal function and be able to comply with oral dosing requirements, with specific instructions for administration and monitoring 5, 6.

The provider must specify which single bone-targeted agent is being requested, with concurrent use of denosumab and ibandronate not approved due to increased risk of severe adverse events 1, 2.
Complete clinical documentation, including DEXA scan results, ADT status, laboratory values, and fracture risk assessment, must be provided before approval can be determined 1, 2, 6.
Dental evaluation and confirmation of calcium and vitamin D supplementation are also required before initiation of therapy 5, 6.